ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.13, Briefing.com reports. ACADIA Pharmaceuticals had a negative net margin of 28.05% and a negative return on equity of 35.70%. The company had revenue of […]

Related Keywords

Alger ,Algeria ,Brendan Teehan ,James Kihara ,Pharmaceuticals Inc ,Pharmaceuticals Trading Down ,Securities Exchange Commission ,Canaccord Genuity Group ,Fred Alger Management ,Jpmorgan Chase Co ,Squarepoint Ops ,Thrivent Financial For Lutherans ,Pharmaceuticals Daily ,Pharmaceuticals Company Profile ,Acadia Pharmaceuticals ,Ameriprise Financial Inc ,Get Free Report ,Trading Down ,Genuity Group ,Exchange Commission ,Alger Management ,Nasdaq Acad ,Facad ,Medical ,Earnings ,